Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting

Obagi Medical (NASDAQ: WALD), part of Waldencast, shared new clinical and real-world data at the Music City SCALE meeting.

Rhea-AI Summary

Obagi Medical (NASDAQ: WALD), part of Waldencast, shared new clinical and real-world data at the Music City SCALE meeting. Highlights include interim results from the ALOHA real-world evaluation of Obagi Saypha MagIQ filler and first data from the NU-GEN Cellular Renewal Serum clinical program.

The ALOHA interim data show 94% of injectors believe MagIQ complements existing fillers, with 43% of patients also evaluating Obagi skincare. NU-GEN is clinically proven to visibly rewind skin’s age by up to six years while addressing nine signs of aging.

Argus May 15 session

-9.82% close to close Open Argus

Details

News Market Reaction – WALD

In the May 15 session, WALD declined 9.82%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.8% in the session following this news. A negative reaction despite positive-sound...

Analysis

The stock moved -9.8% in the session following this news. A negative reaction despite positive-sounding clinical and real-world data would fit prior instances where NU-GEN™ and ALOHA announcements coincided with declines of 7.38% and 8.28%. This pattern suggests that innovation updates have sometimes been overshadowed by broader concerns embedded in the stock. Future earnings trends, commercialization traction, and execution across Obagi programs have historically been key to reshaping sentiment after such drops.

Key Figures

Study duration: 12 weeks Participating sites: over 300 sites Injector satisfaction: 94% of injectors +5 more

Study duration

12 weeks

Open-label NU-GEN Cellular Renewal Serum study

Participating sites

over 300 sites

ALOHA Program real-world evaluation of Obagi Saypha MagIQ

Injector satisfaction

94% of injectors

Believe Obagi Saypha MagIQ complements current filler options

Skincare cross-evaluation

43% of patients

Also evaluating Obagi skincare in ALOHA interim data

Visible age reversal

up to six years

NU-GEN formula clinically proven visible skin age change

Signs of aging addressed

nine signs

NU-GEN Cellular Renewal Serum clinical program

FY2025 net revenue

$272.1M

Full-year 2025 net revenue (flat YoY)

FY2025 Adjusted EBITDA

$16.1M

Adjusted EBITDA for FY2025

Historical Context

5 past events · Latest: Apr 30

5 events

1. Apr 30

   Product launch

   24h Move

   +16.6%

   Launch of new Sun Shield Mineral UV Barrier Protect SPF 40 sunscreen.

2. Apr 28

   Regulatory update

   24h Move

   -2.1%

   SEC concluded investigation without intent to recommend enforcement action.

3. Mar 24

   Product launch

   24h Move

   -7.4%

   Launch of NU-GEN Cellular Renewal Serum with favorable clinical metrics.

4. Mar 19

   Collaboration

   24h Move

   -8.3%

   Collaboration with ProMD in ALOHA Program for saypha MagIQ real-world data.

5. Mar 13

   Earnings results

   24h Move

   +8.2%

   Q4/FY2025 results with $272.1M revenue, positive adjusted EBITDA, lower net debt.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hyaluronic acid dermal filler, fda, nad+

3 terms

hyaluronic acid dermal filler medical

"real-world evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction..."

A hyaluronic acid dermal filler is a gel-based injectable made from a natural sugar that adds volume beneath the skin to smooth wrinkles, plump lips or reshape facial contours; it works like a soft cushion that attracts and holds water to restore lost fullness. Investors care because sales, regulatory approvals, safety records and repeat treatments drive revenue and profitability for makers; changes in demand, competition or safety alerts can quickly affect a manufacturer's market value.

fda regulatory

"pivotal clinical sites for the FDA registration programs for the Obagi fillers..."

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

nad+ medical

"helping replenish skin cells with NAD+ and addressing nine signs of skin aging..."

NAD+ is a naturally occurring molecule that helps cells turn food into usable energy and repair damage, acting like a battery and maintenance signal inside every cell. It matters to investors because drugs, supplements, or diagnostics that raise or measure NAD+ levels are a growing area of medical and consumer interest, with potential revenue, regulatory scrutiny, and clinical risk tied to claims about aging, metabolism, and disease treatment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN.

• Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and Perceived Skin Age: ePoster Dr. Todd Schlessinger, MD
  
  
• Interim Results from a large scale Multiple Practitioner Real-World Evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction with Medical Grade Skin Care: ePoster Dr. Carolyn Jacob, MD
  
  

“As one of the pivotal clinical sites for the FDA registration programs for the Obagi fillers, I was intrigued to do a real-world evaluation of Obagi Saypha^® MagIQ™,” said Dr. Carolyn Jacob, MD. “Reviewing the results from over 300 participating sites validated the core clinical results and makes it clear that there is a place for MagIQ in most practices.”

The real-world data evaluated an interim review of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, a structured clinical collaboration program designed to accelerate aesthetic innovation through practice-led insight. Obagi anticipates that the ALOHA program will become the largest real-world evaluation program for a new injectable filler. The interim data highlights that 94% of injectors believe Obagi Saypha^® MagIQ™ compliments their current filler options and shows 43% of patients also evaluating Obagi skincare.

“These data points represent clinical and real-world results from our newest Obagi innovations,” stated Drew Fine, U.S. General Manager, Professional Channel. “Obagi Saypha^® MagIQ™ and NU-GEN™ Cellular Renewal Serum represent meaningful advances that support practice success and highlight the benefits of looking at Obagi injectable and skincare solutions.”

The ePoster represents the first data sharing from the NU-GEN clinical program. The formula is clinically proven to visibly rewind skin’s age by up to six years¹ by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously.

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm^® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.

Media Contact:
obagi@behrmancesa.com

¹  Results based on a 2025 12-week aging clinical test. Individual results may vary. Data on file at Obagi Cosmeceuticals LLC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What new data did Obagi Medical (NASDAQ: WALD) present at the May 2026 SCALE meeting?

Obagi Medical presented new clinical and real-world data on Obagi Saypha MagIQ filler and NU-GEN Cellular Renewal Serum. According to Obagi, the data came from the ALOHA real-world program and the first NU-GEN clinical program ePoster shared at the event.

What is the Obagi ALOHA program for Saypha MagIQ filler and how large is it expected to be?

The ALOHA program is a structured clinical collaboration evaluating Obagi Saypha MagIQ in real-world practice. According to Obagi, it involves over 300 participating sites and is anticipated to become the largest real-world evaluation program for a new injectable filler.

What interim results were reported for Obagi Saypha MagIQ filler from the ALOHA program (WALD)?

Interim ALOHA data show strong acceptance of Obagi Saypha MagIQ among practitioners. According to Obagi, 94% of injectors believe MagIQ complements their current filler options, and 43% of patients in the program are also evaluating Obagi skincare products alongside the injectable.

What did the NU-GEN Cellular Renewal Serum clinical data reveal for Obagi Medical (WALD)?

The NU-GEN Cellular Renewal Serum data represent the first clinical readout from this program. According to Obagi, the serum is clinically proven to visibly rewind skin’s age by up to six years by replenishing skin cells with NAD+ and addressing nine signs of aging simultaneously.

How could Obagi’s MagIQ filler and NU-GEN Serum support aesthetic practice success for WALD stakeholders?

MagIQ and NU-GEN may strengthen Obagi’s position in injectables and skincare for aesthetic practices. According to Obagi, high practitioner satisfaction with MagIQ and NU-GEN’s multi-sign aging benefits are intended to support practice outcomes and encourage combined injectable and skincare use.